Para Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Para Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-7,500	Closed	-$876K	–	15
2016 Q2	$876K	Buy	+7,500	New	+$1.06M	4.54%	8
2014 Q3	–	Sell	-10,000	Closed	-$1.56M	–	43
2014 Q2	$1.56M	Buy	+10,000	New	+$1.58M	0.91%	31
2013 Q3	–	Sell	-20,000	Closed	-$1.84M	–	43
2013 Q2	$1.84M	Buy	+20,000	New	+$1.93M	0.93%	27

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Para Advisors's ALXN Position: Q3 2016 in Review

Para Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2016, closing a stake of 7,500 shares — an estimated $876K sold.

Para Advisors first reported a position in ALXN in Q2 2013 and held it in 3 quarters. The position peaked at $1.84M in Q2 2013. 518 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

Para Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Para Advisors sold 7,500 Alexion Pharmaceuticals shares in Q3 2016, an estimated $876K.
Para Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 3 quarters.
Para Advisors's Alexion Pharmaceuticals position peaked at $1.84M in Q2 2013.
518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on Para Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.